• CAPA Under QMSR: Root Cause, Risk, and Effectiveness Verification
  • CAPA Under QMSR: Root Cause, Risk, and Effectiveness Verification

    • Speaker : Robert H. Caldwell
    • Session Code : RCJUL2326
    • Date : 23rd July 2026
    • Time : 1:00 PM Eastern Time / 10:00 AM Pacific Time
    • Duration : 75 Mins

Overview:

 

CAPA is one of the most closely examined parts of a medical device quality system, and under FDA’s Quality Management System Regulation, it now carries a different inspection meaning. With QMSR in effect as of February 2, 2026, medical device manufacturers must be prepared to show that their corrective and preventive action processes are not only documented, but risk-based, evidence-driven, and capable of standing up to FDA review under the new inspection approach.

 

This webinar provides a practical review of CAPA in the QMSR inspection era, with a focus on root cause, risk, and effectiveness verification. The session explains how corrective action and preventive action are now treated as distinct processes under ISO 13485, why old combined CAPA workflows may create inspection risk, and how FDA investigators may connect CAPA records with complaints, nonconformances, risk files, management review, internal audits, and effectiveness data.

 

Rather than treating CAPA as a form-closing exercise, this program shows how to build CAPA records that tell a clear and defensible story: what happened, why it happened, how far the issue may reach, what risk decision was made, what action was taken, and how the organization verified that the problem was actually solved. Attendees will also learn how repeat issues, weak root-cause analysis, undocumented risk decisions, and checklist-style effectiveness checks can expose deeper quality system weaknesses during inspection.

 

The session is designed for quality, regulatory, compliance, and operations professionals who need to review their CAPA process through the QMSR lens and identify where existing procedures, records, and closure practices may need improvement before they are tested by FDA.

 

Areas Covered:

 

  • What changed for CAPA under FDA’s QMSR effective February 2, 2026
  • How the new inspection approach under CP 7382.850 changes the way CAPA records may be reviewed
  • The practical difference between corrective action and preventive action under ISO 13485
  • Why combined CAPA workflows may create inspection risk if triggers, records, and evidence are not clearly separated
  • How to distinguish symptoms, proximate causes, and true systemic root causes
  • Common root-cause mistakes, including “operator error,” weak retraining fixes, and stopping at the first plausible cause
  • How to connect CAPA decisions to risk management and determine when an issue requires correction only or formal CAPA
  • What a defensible risk-based CAPA record should show
  • Why effectiveness verification must prove the problem was actually solved, not just that action items were completed
  • How repeat or similar CAPA issues can become inspection red flags
  • How FDA investigators may trace CAPA from complaints, nonconformances, risk files, management review, and closure evidence
  • Practical questions quality teams can use to review CAPA readiness under the QMSR inspection lens

 

To support implementation of the concepts discussed during the webinar, attendees will receive the following handouts:

 

  • QMSR CAPA Readiness Self-Check Checklist
  • Risk-Based CAPA Triage Scenario Worksheet

 

Why should you attend?

 

CAPA has always been one of the most inspection-sensitive parts of a medical device quality system, but under FDA’s QMSR inspection era, the way CAPA records are reviewed is changing. It is no longer enough to show that a CAPA was opened, action items were completed, and the file was closed. Quality teams must be able to show that the issue was properly investigated, the root cause was systemic, the risk decision was documented, the scope was justified, and the effectiveness check proved the problem was actually solved.

 

This webinar will help attendees look at CAPA through the lens of QMSR and CP 7382.850. The session explains where older CAPA habits may create inspection risk, including blurred corrective and preventive action workflows, weak “operator error” conclusions, correction-only decisions without risk rationale, and effectiveness checks that only confirm completion rather than results.

 

Attendees will gain a practical understanding of how to build CAPA records that tell a clear and defensible story: what happened, why it happened, how far the issue may reach, what risk decision was made, what action was taken, and how the organization verified that the fix worked. For quality, regulatory, and compliance teams preparing for FDA inspections under QMSR, this session offers a timely opportunity to reassess CAPA practices before an investigator does it for them.

 

Who Will Benefit?

 

This webinar is designed for medical device professionals responsible for CAPA, quality system compliance, inspection readiness, complaint/nonconformance handling, risk-based decisions, and effectiveness verification under FDA’s QMSR framework.

Those include:

 

  • Quality Assurance Managers
  • Quality Systems Managers
  • CAPA Managers
  • CAPA Specialists
  • Quality Engineers
  • Senior Quality Engineers
  • Regulatory Affairs Managers
  • Regulatory Compliance Managers
  • Medical Device Compliance Managers
  • Complaint Handling Managers
  • Post-Market Surveillance Managers
  • Nonconformance/CAPA Coordinators
  • Corrective and Preventive Action Owners
  • Risk Management Specialists
  • ISO 13485 Compliance Professionals
  • Internal Audit Managers
  • Supplier Quality Managers
  • Manufacturing Quality Managers
  • Operations Quality Leaders
  • Quality Directors
  • VPs of Quality
  • Medical Device Consultants

 

Robert H. Caldwell is a medical device quality systems and regulatory compliance professional with extensive experience helping manufacturers strengthen CAPA, complaint handling, risk management, supplier quality, and inspection readiness programs.


Over the course of his career, he has worked closely with quality, regulatory, engineering, operations, and executive teams to investigate nonconformances, improve root-cause analysis, respond to FDA inspection findings, and build CAPA systems that are practical, risk-based, and defensible. His work has included supporting medical device organizations through FDA inspections, Form 483 responses, remediation activities, internal audits, management review improvements, and quality system gap assessments.


His areas of focus include FDA’s Quality Management System Regulation, ISO 13485, ISO 14971 risk management, corrective and preventive action, effectiveness verification, complaint and nonconformance trending, and the connection between CAPA records and broader quality system evidence.


Known for his clear and practical teaching style, Robert H. Caldwell translates complex regulatory expectations into real-world quality system actions. He helps teams understand not only what the regulation requires, but how CAPA records may be read by investigators, where weak documentation creates risk, and how to build records that show sound reasoning, appropriate risk decisions, and verified effectiveness.



Write a review

Please login or register to review

Enrollment Options

 
 
 
 
 
 

Tags: QMSR, CAPA, FDA Inspection Readiness, Medical Device Compliance, Root Cause Analysis, Risk-Based CAPA, Effectiveness Verification, ISO 13485, ISO 14971, Corrective Action, Preventive Action, CP 7382.850, Quality Systems, Form 483, Medical Device Quality, Robert Caldwell, July 2026